Reduction of the angiogenesis score and tumor growth in subcutaneously implanted colon carcinoma in a mouse model;Leflunomid reduziert den Angiogenese-score und das Tumorwachstum subkutan implantierter Kolonkarzinomzellen im Mausmodell

Chirurg

Volumn 73, Issue 7, 2002, Pages 716-720

  Mall, J W ^a,c   Myers, J A ^b   Xu, X ^b   Saclarides, T J ^b   Philipp, A W ^a   Pollmann, C ^a  

^a Henriettenstiftung Hannover   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis inhibition; Leflunomide; Tyrosine kinase receptor

Indexed keywords

ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; URIDINE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CAPILLARY; CELL DIVISION; CELL STRAIN HT29; COLON TUMOR; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZATION; VASCULARIZATION;

ADMINISTRATION, ORAL; ANIMALS; CAPILLARIES; CELL DIVISION; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; INJECTIONS, INTRAPERITONEAL; ISOXAZOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; URIDINE;

EID: 0036653135     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-002-0453-1     Document Type: Article

References (25)

1. Coltrera MD, Wang J, Porter PL, Gown AM (1995) Expression of plateled derived growth factor B-chain and the plateled derived growth factor receptor β-subunit in human breast tissue and breast carcinoma. Cancer Res 55:2703-2708
2. De Jong JS, van Diest PJ, van der Valk P, Baak JP (2001) Expression of growth factors, growth factor receptors and apoptosis related proteins in breast cancer: relation to apoptotic rate. Breast Cancer Res Treat Apr 66:201-208
3. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
4. Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
5. Frank RE, Saclarides TJ, Leurgans S et al. (1995) Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222:695-699
6. Gasparini G (1994). Quantification of intratumoral vascularization predicts metastasis in human invasive solid tumors.Oncol Rep 1:7-12
7. Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153
8. Kalden JR, Schattenkirchner M, Smolen JS (2000). Leflunomide vs Sulfasalazin in rheumatoid arthritis: 24 month update of a randomized double - blind study. Arth Rheum 42 [Suppl]:Abstract 1202
9. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM (2001) Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesisinhibitorTNP-470.Cancer Res 61:5491-5498
10. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A (1995) Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 334:161-164
11. Mendel DB, Laird AD, Smolich BD, Blake RA et al. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15:29-41 (Review)
12. Myers JA, Mehta P, Hunter AW, Bernstein SA, Erickson P (1995) Automated double-label immunohistochemistry.J Surg Path 1:105-113
13. Neal DE, Marsh C, Bennett MK, Abel PD et al. (1985) Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet 1:366-368
14. O'Reilly MS, Holmgren L, Shing Y et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma.Cell 79:315-328
15. Reinhold-Keller E, Gross WL (2001) Leflunomid zur Behandlung der rheumatoiden Arthritis. Dtsch Ärztebl 98;29:1502-1507
16. Shawver LK, Schwartz DP, Mann E et al. (1997) Inhibition of plateled derived growth factor mediated signal transduction and tumor growth by N-[4-(trifluormethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 3:1167-1177
17. Singhal S, Mehta J, Desikan R et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. NEJM 341:1565-1571
18. Stephens TD, Bunde CJW, Fillmore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharm 12:1489-1499
19. Vacca A, Ribatti D, Presta M et al. (1999) Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3054-3073
20. Weidner N, Carroll PR, Flax J, Blumefeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409
21. Xu X, Shen J, Mall JW et al.(1999) In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 58:1405-1413
22. Xu X, Williams JW, Bremer EG, Finnegan A, Chong ASF (1995) Inhibition of protein tyrosine kinase phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 270:12398-12403
23. Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG (2000) Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol 46:249-259
24. Barinaga M (1997) From bench top to bedside. Science 278:1036-1039
25. Waldman WJ, Bickerstaff A, Gordillo G, Orosz K, Knight DA, Orosz CG (2001) Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. Transplantation 72:1578-1582